Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Küker, W.
Right arrow Articles by Herrlinger, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Küker, W.
Right arrow Articles by Herrlinger, U.
Related Collections
Right arrow MRI
Right arrow Primary brain tumor
NEUROLOGY 2005;65:1129-1131
© 2005 American Academy of Neurology


Brief Communications

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised

W. Küker, MD, T. Nägele, MD, E. Thiel, MD, M. Weller, MD and U. Herrlinger, MD

From the Departments of Neuroradiology (Drs. Küker and Nägele) and Neurology (Drs. Weller and Herrlinger), Medical School, University of Tübingen; Department of Hematology and Oncology (Dr. Thiel), University Hospital Benjamin Franklin, Berlin, Germany; and Department of Neuroradiology (Dr. Küker), The Radcliffe Infirmary, Oxford, UK.

Address correspondence and reprint requests to Dr. Wilhelm Küker, Department of Neuroradiology, The Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK; e-mail: wilhelm.kueker{at}orh.nhs.uk

The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.


Disclosure: The authors report no conflicts of interest.

Received May 16, 2005. Accepted in final form June 16, 2005.




This article has been cited by other articles:


Home page
NeurologyHome page
U. Schlegel, A. Jurgens, H. Pels, W . Kuker, and U. Herrlinger
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised
Neurology, April 25, 2006; 66(8): 1287 - 1287.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised
Uwe Schlegel, et al.
Neurology Online, 5 Dec 2005 [Full text]
Reply from Authors
W. Kuker, et al.
Neurology Online, 5 Dec 2005 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.